By systematically reviewing the preclinical and clinical data reported for BTK inhibitors, this review focuses on the mechanism of action of BTK inhibitors in PCNSL and the results of existing clinical trials and discusses their therapeutic efficacy, challenges, and future development directions, aiming to provide new perspectives and broader possibilities for treating PCNSL. This evidence concerns the gene BTK and primary central nervous system lymphoma.